NF1 Microdeletion Syndrome: Comprehensive Disease-Characteristics Report

Executive summary

NF1 microdeletion syndrome is a severe, contiguous-gene subtype of neurofibromatosis type 1 (NF1) caused by a constitutional heterozygous deletion at 17q11.2 encompassing NF1 and neighboring genes. The canonical recurrent type-1 deletion is approximately 1.4 Mb, removes 14 protein-coding genes and four microRNA genes, and constitutes roughly 70–80% of NF1 microdeletions. Large deletions collectively account for approximately 5–11% of molecularly diagnosed NF1, although ascertainment and testing methods affect estimates. Compared with intragenic NF1 pathogenic variants, non-mosaic deletions are associated with earlier and heavier neurofibroma burden, dysmorphism, childhood overgrowth, developmental and learning problems, cardiovascular abnormalities, and higher malignant peripheral nerve sheath tumor (MPNST) risk. (pacot2024correlationbetweenlarge pages 1-2, tritto2024geneticepigeneticeffectsin pages 1-2, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)

Two important recent developments are: (1) a 2024 human molecular study showing that the deletion changes local three-dimensional chromatin interactions and expression of genes outside the deleted interval; and (2) explicit recognition in 2024 pediatric surveillance recommendations that an NF1 microdeletion involving SUZ12 is a high-risk cancer-predisposition genotype. (tritto2024geneticepigeneticeffectsin pages 1-2, perrino2024updateonpediatric pages 6-8)

Table: This table condenses the key knowledge-base facts for NF1 microdeletion syndrome, including identifiers, recurrent deletion classes, major co-deleted genes, core clinical risks, mechanisms, diagnostics, surveillance, and treatment framing. It is aligned to the gathered evidence and highlights where 2024 studies added mechanistic and surveillance updates.

1. Disease information

Definition and category

Disease name: NF1 microdeletion syndrome.
Category: rare autosomal-dominant genomic disorder; chromosome 17q11.2 contiguous-gene deletion syndrome; RASopathy; neurocutaneous and tumor-predisposition syndrome.

The preferred definition is a constitutional or mosaic heterozygous deletion encompassing NF1, rather than merely an intragenic NF1 deletion. “NF1 deletion syndrome,” “NF1 microdeletion syndrome,” “17q11.2 microdeletion syndrome,” “17q11 microdeletion syndrome,” “NF1 total-gene deletion,” and “chromosome 17q11.2 deletion syndrome, 1.4 Mb” are common alternative terms. The literature sometimes uses total gene deletion (TGD), especially in experimental studies. (pacot2024correlationbetweenlarge pages 1-2, wegscheid2021patientderivedipsccerebralorganoid pages 1-4)

Identifiers

• MONDO: MONDO:0013357, chromosome 17q11.2 deletion syndrome, 1.4 Mb.
• Orphanet: ORPHA:97685, 17q11 microdeletion syndrome.
• OMIM: the broader allelic disorder is NF1, OMIM 162200; a separate universally applied OMIM phenotype number for the microdeletion subtype was not established in the retrieved evidence.
• MeSH: generally indexed under Neurofibromatosis 1 and Chromosome Deletion rather than a dedicated microdeletion heading.
• ICD-10/ICD-11: typically coded under NF1/neurofibromatosis; no microdeletion-specific billable code was identified. The copy-number diagnosis should therefore be retained separately in the molecular record.

OpenTargets associates MONDO:0013357 principally with NF1 and RNF135, while ORPHA:97685 is represented as 17q11 microdeletion syndrome. (OpenTargets Search: NF1 microdeletion syndrome)

Evidence granularity

Most information is aggregated from disease resources, small retrospective cohorts, molecular case series, and reviews—not population-scale EHR data. Key recent primary data include cohorts of 17 and 22 affected individuals and a 2024 qPCR/4C-seq/NGS study. Consequently, precise phenotype frequencies remain less secure than the direction of genotype–phenotype associations. (pacot2024correlationbetweenlarge pages 1-2, tritto2024geneticepigeneticeffectsin pages 1-2, buki2021genotypephenotypeassociationsin pages 1-2)

2. Etiology

Causal genetic factor

The cause is heterozygous loss of NF1 plus a variable set of flanking genes at chromosome 17q11.2. Recurrent deletion classes are:

• Type 1: approximately 1.4 Mb; about 70–80% of deletions; usually germline and non-mosaic; caused by non-allelic homologous recombination (NAHR) between low-copy repeats NF1-REPa and NF1-REPc, classically during maternal meiosis. It removes 14 protein-coding genes and four microRNA genes.
• Type 2: approximately 1.2 Mb; roughly 10–20%; mediated by recombination involving SUZ12 and its pseudogene SUZ12P1; frequently postzygotic and therefore mosaic; approximately 13 coding genes are hemizygous.
• Type 3: approximately 1.0 Mb; approximately 1–4%; recurrent breakpoints involving NF1-REPb and NF1-REPc.
• Atypical deletions: nonrecurrent, variable breakpoints and size. A 2021 cohort documented approximately 0.60–7 Mb deletions and several novel configurations. (pacot2024correlationbetweenlarge pages 1-2, buki2021genotypephenotypeassociationsin pages 1-2, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3, buki2021genotypephenotypeassociationsin pages 14-15)

These are pathogenic structural variants causing loss of function/haploinsufficiency. They are germline when present constitutionally, but postzygotic deletions can generate somatic mosaicism. The causal allele is expected to be absent or extremely rare from general-population databases; population allele frequency is not a meaningful carrier-frequency measure for recurrent pathogenic CNVs.

Risk and modifier factors

The strongest disease risk factor is carrying the deletion. For tumor formation, constitutional NF1 haploinsufficiency is followed by somatic inactivation of the remaining NF1 allele in susceptible cells. Co-deletion of SUZ12, encoding a Polycomb repressive complex 2 component, is associated with particularly elevated MPNST risk. Candidate contributors to specific manifestations include RNF135 for overgrowth/dysmorphism, ADAP2 for cardiovascular development, and CRLF3 for neurodevelopment. Additional CNVs and rare RAS-pathway variants may modify expressivity, but these findings are preliminary. (pacot2024correlationbetweenlarge pages 1-2, tritto2024geneticepigeneticeffectsin pages 1-2, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)

Environmental, protective, and gene–environment factors

No environmental exposure, infection, toxin, diet, or lifestyle behavior is known to cause the constitutional deletion. No validated genetic or environmental protective factor prevents the syndrome. Ionizing radiation is generally avoided when equivalent non-ionizing surveillance is available because NF1 is a tumor-predisposition disorder, but this is complication-risk management rather than prevention of the deletion. Robust microdeletion-specific gene–environment interactions have not been demonstrated.

3. Phenotypes

The phenotype combines ordinary NF1 manifestations with a higher probability of severe developmental, dysmorphic, connective-tissue, cardiovascular, and tumor features. Manifestations are strongly age-dependent; absence in a young child does not predict absence later. (buki2021genotypephenotypeassociationsin pages 1-2, buki2021genotypephenotypeassociationsin pages 14-15)

Major phenotype groups and ontology suggestions

• Pigmentary signs: café-au-lait macules (HP:0000957) and axillary/inguinal freckling (HP:0000997). Usually begin in infancy or early childhood; generally persistent and medically mild, although visible disease may affect psychosocial well-being.
• Neurofibromas: cutaneous neurofibromas (HP:0001067), subcutaneous neurofibromas, plexiform neurofibroma (HP:0009732), and spinal/internal neurofibromas. Cutaneous lesions often appear earlier and in larger numbers than in non-deletion NF1; internal tumor burden can be progressive. Non-mosaic deletion patients are enriched for extreme internal tumor volume exceeding 3,000 mL and sometimes more than 1,000 neurofibromas. Pain, disfigurement, neurologic compromise, mobility limitation, and fear of malignancy substantially impair quality of life. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 17-18)
• MPNST: malignant peripheral nerve sheath tumor (HP:0100697). Lifetime risk estimates are approximately 16–26%, compared with 8–13% across NF1 more generally. New persistent pain, rapid growth, hardening, neurologic deficit, or altered texture in a pre-existing tumor are concerning. (pacot2024correlationbetweenlarge pages 1-2, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)
• Neurodevelopment: global developmental delay (HP:0001263), intellectual disability (HP:0001249), learning disability (HP:0001328), speech delay (HP:0000750), attention/behavioral problems, and autistic traits. These emerge primarily in childhood, vary from mild learning problems to substantial impairment, and can affect education, independence, and family functioning. (buki2021genotypephenotypeassociationsin pages 1-2, wegscheid2021patientderivedipsccerebralorganoid pages 1-4)
• Growth and craniofacial morphology: childhood overgrowth/tall stature (HP:0000098 or age-specific growth terms), macrocephaly (HP:0000256), large hands and feet, and characteristic facial dysmorphism (HP:0001999). Overgrowth may be most prominent in childhood and is more characteristic of type-1 than some atypical deletions. (buki2021genotypephenotypeassociationsin pages 1-2, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)
• Musculoskeletal/connective tissue: muscular hypotonia (HP:0001252), joint hypermobility (HP:0001382), scoliosis (HP:0002650), and bone lesions. Severity is variable; consequences include delayed motor skills, pain, reduced endurance, and orthopedic disability. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3, buki2021genotypephenotypeassociationsin pages 14-15)
• Cardiovascular: congenital heart defects (HP:0001627) and other cardiovascular malformations occur more often than in intragenic NF1 cohorts. NF1-associated hypertension and vasculopathy remain clinically relevant even though they are not unique to the deletion. (pacot2024correlationbetweenlarge pages 1-2, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)
• Other conventional NF1 findings: optic pathway glioma, Lisch nodules, choroidal abnormalities, osseous dysplasia, and endocrine complications may occur, but the retrieved microdeletion evidence does not establish reliable subtype-specific percentages.

A 17-patient pediatric-enriched series found that dysmorphism, macrocephaly, large hands/feet, developmental or learning difficulties, speech problems, and overgrowth were more common than among individuals with intragenic NF1 variants; macrocephaly, neurobehavioral problems, and overgrowth were less frequent in atypical than type-1 deletions. Exact percentages from such small cohorts should not be generalized. (buki2021genotypephenotypeassociationsin pages 1-2)

4. Genetic and molecular information

Principal genes and structural variant classification

• NF1 encodes neurofibromin, a tumor suppressor and negative regulator of RAS signaling. Its constitutional deletion is pathogenic through haploinsufficiency; tumor initiation generally requires somatic loss/inactivation of the remaining allele.
• SUZ12 is loss-of-function constrained and encodes a core PRC2 component. Constitutional hemizygosity and subsequent tumor-level PRC2 disruption plausibly explain part of the elevated malignancy risk.
• RNF135 is implicated in overgrowth and facial dysmorphism; OpenTargets links it to MONDO:0013357.
• CRLF3 has experimental support for neurodevelopmental effects.
• ADAP2 is a candidate contributor to cardiovascular abnormalities.
• Other haploinsufficient or biologically plausible interval genes include ATAD5, OMG, RAB11FIP4, PSMD11, CDK5R1, and ASIC2. (OpenTargets Search: NF1 microdeletion syndrome, tritto2024geneticepigeneticeffectsin pages 1-2, buki2021genotypephenotypeassociationsin pages 14-15, wegscheid2021patientderivedipsccerebralorganoid pages 1-4)

Clinically detected recurrent or atypical deletions encompassing NF1 are classified as pathogenic/likely pathogenic CNVs using ACMG/ClinGen copy-number standards, considering haploinsufficient genes, deletion size, inheritance, and phenotype. The exact genomic coordinates and genome assembly must be recorded; “1.4 Mb deletion” alone is insufficient for atypical cases.

Modifiers and epigenetics

The 2024 Human Genetics study showed that pathogenesis extends beyond simple dosage loss. In type-1 deletion cells, 4C-seq detected changed breakpoint-flanking DNA contacts, including an acquired interaction between the RHOT1 promoter and SLC6A4, accompanied by increased SLC6A4 expression. The authors’ abstract states that the deletion “leads to changes in the 3D chromatin structure” and “likely causes position effect on the expression of deletion flanking genes.” Rare likely pathogenic RAS-pathway variants were also detected in individuals with incidental features. These results are important but require replication in larger cohorts and disease-relevant tissues. (tritto2024geneticepigeneticeffectsin pages 1-2)

5. Environmental information

Environmental factors do not cause NF1 microdeletion syndrome. Smoking, alcohol, diet, exercise, occupational exposures, pollution, and infectious agents have no established etiologic role. Healthy activity, nutrition, sleep, and avoidance of smoking support general health but are not proven to alter the underlying genomic disorder. No zoonotic or transmissible component exists.

6. Mechanism and pathophysiology

Upstream causal chain

17q11.2 deletion → reduced NF1/neurofibromin dosage → excessive RAS-GTP signaling → increased RAF–MEK–ERK and PI3K–AKT–mTOR activity → altered proliferation, differentiation, and survival. In peripheral nerve tumors, a second somatic NF1 hit in the Schwann-cell lineage initiates tumor formation; interactions with fibroblasts, mast cells, macrophages, neurons, and extracellular matrix support neurofibroma growth. Suggested GO terms include negative regulation of RAS protein signal transduction (GO:0046580), RAS protein signal transduction (GO:0007265), MAPK cascade (GO:0000165), regulation of cell proliferation (GO:0042127), and peripheral nervous system development (GO:0007422).

Malignant progression

Biallelic NF1 loss → plexiform neurofibroma → additional lesions such as CDKN2A loss → ANNUBP → PRC2 disruption through SUZ12/EED loss → broad chromatin dysregulation and MPNST. Constitutional SUZ12 co-deletion lowers the dosage reserve and is a plausible reason deletion carriers represent a high-risk subgroup. Relevant cell types include Schwann cell (CL:0002573), Schwann-cell precursor/neural-crest derivatives, fibroblast (CL:0000057), mast cell (CL:0000097), and macrophage (CL:0000235). (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)

Neurodevelopmental mechanism

Patient-derived cerebral organoids separated NF1-related progenitor proliferation from a CRLF3–δ-catenin–RhoA neuronal-maturation pathway. CRLF3 reduction increased immature neurons early, reduced mature neurons later, increased apoptosis, reduced dendritic maturation, and decreased N-cadherin, Rac1, and RhoA activity. Pharmacologic RhoA activation with CN03 rescued maturation and neurite growth. A germline CRLF3 p.Leu389Pro variant was also associated with greater autistic-trait burden in an NF1 cohort. Suggested GO terms include neurogenesis (GO:0022008), neuron differentiation (GO:0030182), dendrite development (GO:0016358), apoptotic process (GO:0006915), and Rho protein signal transduction (GO:0007266). Relevant cell terms include neural stem cell (CL:0000047), neural progenitor cell, and neuron (CL:0000540). (wegscheid2021patientderivedipsccerebralorganoid pages 8-9, wegscheid2021patientderivedipsccerebralorganoid pages 1-4)

Molecular profiling and advanced technologies

Available approaches include RNA-seq, qPCR, 4C-seq, exome/NGS modifier analysis, RAS/Rac1/RhoA assays, patient-derived iPSC neural cultures, and cerebral organoids. The 2024 chromatin study and 2021 organoid study represent the strongest microdeletion-specific functional evidence retrieved. No validated microdeletion-specific metabolomic, lipidomic, single-cell atlas, or spatial-transcriptomic signature was identified. (tritto2024geneticepigeneticeffectsin pages 1-2, wegscheid2021patientderivedipsccerebralorganoid pages 9-10, wegscheid2021patientderivedipsccerebralorganoid pages 16-17)

7. Anatomical structures affected

NF1 microdeletion syndrome is multisystemic:

• Peripheral nervous system: peripheral nerves, nerve roots, plexuses, and Schwann-cell lineage; suggested UBERON terms include peripheral nervous system (UBERON:0000010), peripheral nerve (UBERON:0001021), and spinal nerve root.
• Central nervous system: brain, optic pathway, and neurodevelopmental circuits; UBERON:0000955 (brain), UBERON:0000966 (retina), and optic nerve terms.
• Skin/subcutis: melanocytes and cutaneous peripheral nerves; UBERON:0002097 (skin of body).
• Skeleton and connective tissue: vertebral column, long bones, joints, and soft tissue.
• Cardiovascular system: heart and blood vessels.
• Subcellular compartments: cytosolic RAS signaling machinery, nucleus/chromatin and PRC2, plasma-membrane adhesion complexes, and neuronal cytoskeleton. Suggested GO cellular components include nucleus (GO:0005634), chromatin (GO:0000785), cytoplasm (GO:0005737), plasma membrane (GO:0005886), and dendrite (GO:0030425).

Lesions may be localized, diffuse, unilateral, bilateral, or asymmetric; no syndrome-wide lateralization is expected.

8. Temporal development

The deletion is congenital and the disorder is lifelong, but clinical expression is insidious and age dependent. Pigmentary findings often emerge first in infancy. Developmental, speech, behavioral, growth, and congenital cardiovascular features become apparent in early childhood. Plexiform neurofibromas may be congenital or childhood-onset; cutaneous neurofibromas usually accumulate later and can appear earlier and at greater burden in deletion carriers. MPNST risk becomes particularly important from adolescence through adulthood. (pacot2024correlationbetweenlarge pages 1-2, buki2021genotypephenotypeassociationsin pages 1-2)

There are no formal stages for the constitutional syndrome. Tumor evolution can be conceptualized as benign PN → atypical lesion/ANNUBP → MPNST. NF1 itself does not remit. Individual tumors may stabilize, grow, respond to therapy, recur, or transform. Critical intervention windows include early developmental assessment, childhood vision surveillance, recognition of growing plexiform neurofibromas, and rapid investigation of malignant warning symptoms.

9. Inheritance and population

The syndrome follows autosomal-dominant inheritance. NF1-related manifestations have essentially complete lifetime penetrance, but expressivity is highly variable and age dependent. Clinically unaffected constitutional carriers of a full germline type-1 deletion have not been reported in the reviewed literature. Mosaic type-2 or atypical deletions may be milder depending on tissue distribution. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 17-18)

Many deletions arise de novo. An affected non-mosaic individual has a theoretical 50% transmission risk in each pregnancy. Parental testing is needed to distinguish de novo occurrence, inherited deletion, and parental mosaicism. Germline mosaicism is possible but poorly quantified. Anticipation, consanguinity, and classic founder effects are not established. Carrier frequency is not ordinarily calculated for this fully penetrant dominant disorder.

Estimated prevalence is approximately 1 in 60,000, derived from NF1 prevalence near 1:3,000 and microdeletions near 5%; reports place deletions at roughly 4.7–11% of NF1. No reliable annual incidence, geographic enrichment, ethnic predilection, or sex imbalance has been demonstrated. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 17-18)

10. Diagnostics

Clinical diagnosis

Patients meet the revised clinical framework for NF1 through combinations of café-au-lait macules, freckling, neurofibromas/plexiform neurofibroma, optic pathway glioma, ocular findings, characteristic osseous lesions, an affected parent, or a heterozygous pathogenic NF1 variant. However, early childhood diagnosis can be difficult because many criteria are age dependent. Dysmorphism, overgrowth, developmental delay, congenital heart disease, unusually early neurofibromas, or high tumor load should prompt deletion analysis. (buki2021genotypephenotypeassociationsin pages 1-2, buki2021genotypephenotypeassociationsin pages 14-15)

Recommended molecular workflow

1. Use an NF1 assay capable of detecting both sequence variants and exon/whole-gene copy-number changes.
2. If sequencing is negative or dosage loss is suspected, perform MLPA, validated NGS copy-number analysis, or another dosage assay.
3. Confirm and define the interval with chromosomal microarray/array-CGH; this identifies co-deleted genes and atypical extension.
4. Consider breakpoint-specific testing, digital PCR, qPCR, or FISH for confirmation, familial testing, or suspected mosaicism.
5. WGS can define breakpoints and complex rearrangements; WES may detect dosage changes only if the analytical pipeline is validated and is inferior to CMA for defining a contiguous deletion.
6. Conventional karyotyping has low resolution and is not first line. Mitochondrial and repeat-expansion tests are not relevant. (buki2021genotypephenotypeassociationsin pages 1-2, buki2021genotypephenotypeassociationsin pages 5-6)

In the 2021 study, MLPA was used after systematic NF1 sequencing and array-CGH for classification; 17 deletion-positive patients were characterized, including type-1, type-2, mosaic, and novel atypical deletions. The authors describe MLPA as cost-effective, but breakpoint resolution depends on probe density. (buki2021genotypephenotypeassociationsin pages 1-2, buki2021genotypephenotypeassociationsin pages 5-6)

Clinical evaluation and imaging

Assessment should include skin and neurologic examination, blood pressure, growth and head circumference, developmental/educational screening, ophthalmology, skeletal examination, and cardiovascular evaluation guided by findings. MRI is preferred for symptomatic lesions. In high-risk patients, 2024 recommendations support baseline whole-body MRI after puberty/late adolescence. For painful or growing lesions suspicious for MPNST, regional MRI with diffusion/ADC mapping and 18F-FDG PET/CT improve characterization; suspicious lesions require multidisciplinary biopsy or resection planning. (perrino2024updateonpediatric pages 6-8)

Differential diagnoses include Legius syndrome/SPRED1, constitutional mismatch-repair deficiency, other RASopathies, isolated café-au-lait macules, segmental/mosaic NF1, and larger or overlapping 17q11.2 CNVs. The distinguishing feature is molecular demonstration of an NF1-containing deletion.

11. Outcome and prognosis

NF1 microdeletion syndrome is generally more morbid than NF1 caused by intragenic variants, but individual outcomes remain unpredictable. Major determinants are deletion type and mosaicism, internal/plexiform tumor burden, SUZ12 involvement, neurologic and developmental impairment, cardiovascular disease, and malignant transformation. (pacot2024correlationbetweenlarge pages 1-2, buki2021genotypephenotypeassociationsin pages 1-2)

The most defensible quantitative prognostic statistic is the 16–26% lifetime MPNST risk, versus approximately 8–13% in general NF1. Non-mosaic patients are more likely to have extreme internal tumor burden. No robust microdeletion-specific five- or ten-year survival curve, life-expectancy estimate, mortality rate, EQ-5D/SF-36 dataset, or validated prognostic calculator was found. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3)

Functional morbidity can include chronic pain, motor limitation, disfigurement, impaired vision, educational difficulties, reduced employment/independence, and repeated surgery or imaging. Recovery from the genomic syndrome is not possible, but specific complications may improve with surgery, targeted therapy, rehabilitation, educational intervention, and pain management.

12. Treatment

There is no treatment that restores the deleted chromosome interval and no therapy approved specifically for NF1 microdeletion syndrome. Management is multidisciplinary and complication directed.

• Plexiform neurofibroma: surgical resection when safely feasible and clinically indicated. For symptomatic, inoperable NF1-associated plexiform neurofibromas, MEK inhibition—most established with selumetinib—targets downstream RAS–RAF–MEK–ERK signaling. This is an NF1 indication, not a microdeletion-specific therapy; deletion carriers should not be presumed to have a different response without data. Monitor cardiac function, ocular toxicity, gastrointestinal effects, creatine kinase, skin/nail toxicity, and adherence according to the product label and specialist protocols. Suggested MAXO: pharmacotherapy, molecularly targeted therapy, tumor surveillance, MRI, and surgical resection.
• Suspected ANNUBP/MPNST: urgent specialist imaging, image-guided biopsy when appropriate, and complete oncologic resection with negative margins when feasible. Chemotherapy and radiotherapy decisions are individualized; the constitutional tumor predisposition and radiation risks require specialist review.
• Developmental/behavioral morbidity: early-intervention services, individualized education, neuropsychological assessment, speech-language therapy, occupational therapy, physical therapy, and treatment of ADHD/anxiety when indicated.
• Pain and functional disease: multimodal analgesia, physiotherapy, rehabilitation, psychological support, and treatment of the causative tumor or orthopedic lesion.
• Cardiovascular/orthopedic/ophthalmic complications: standard specialty treatment tailored to the lesion.

Current NF1 trials include MEK inhibitors and imaging/biomarker strategies, but no retrieved trial was restricted to NF1 microdeletion syndrome. The 2024 recommendations cite NCT06188741, evaluating surveillance and early treatment of asymptomatic high-risk plexiform neurofibromas. Investigational cell-free DNA surveillance is not yet standard care. (perrino2024updateonpediatric pages 6-8)

No validated microdeletion-specific pharmacogenomic rule, gene therapy, cell therapy, RNA therapy, or CRISPR treatment is clinically available. The organoid rescue of CRLF3-related defects by RhoA activation is mechanistic proof-of-concept, not a therapeutic recommendation. (wegscheid2021patientderivedipsccerebralorganoid pages 8-9)

13. Prevention

Primary prevention

The deletion cannot be prevented through lifestyle or immunization. Reproductive options after genetic counseling include prenatal diagnosis by chorionic-villus sampling or amniocentesis and preimplantation genetic testing for a known familial deletion. Testing must be designed to detect the family’s CNV and, where relevant, mosaicism.

Secondary and tertiary prevention

Early molecular confirmation, cascade testing, developmental screening, ophthalmologic surveillance, blood-pressure monitoring, and tumor surveillance can reduce avoidable morbidity. The 2024 high-risk approach recommends baseline whole-body MRI after puberty/late adolescence and closer follow-up when internal tumor burden exceeds 300 mL or a distinct nodular lesion is present. Patients should be educated to report persistent or nocturnal pain, rapid enlargement, hardening, weakness, sensory change, or functional decline promptly. (perrino2024updateonpediatric pages 6-8)

There is no population newborn-screening program, preventive medication, vaccine, dietary prophylaxis, or environmental intervention specific to NF1 microdeletion syndrome.

14. Other species and natural disease

No naturally occurring veterinary syndrome precisely equivalent to the recurrent human 17q11.2 contiguous deletion was identified. NF1/Nf1 orthologs are evolutionarily conserved in mouse (Mus musculus, NCBI Taxon 10090), rat (10116), zebrafish (Danio rerio, 7955), and fruit fly (Drosophila melanogaster, 7227). Naturally occurring peripheral nerve sheath tumors occur in animals, but they should not be equated with the human microdeletion syndrome without genomic confirmation. There is no zoonotic transmission or cross-species contagion.

15. Model organisms and experimental systems

The most disease-specific model is the patient-derived iPSC cerebral-organoid system reported in 2021. Lines from three individuals with 1.4-Mb total-gene deletions and one atypical deletion were differentiated into neural stem cells, two-dimensional neurons, and forebrain cerebral organoids. CRLF3 knockdown phenocopied neuronal survival and maturation abnormalities, and RhoA activation rescued key defects. Strengths include human genetic background, developmental cell types, isogenic perturbations, and functional rescue; limitations include immature organoids, lack of vasculature/immune context, small donor numbers, and uncertain translation to cognition in vivo. (wegscheid2021patientderivedipsccerebralorganoid pages 8-9, wegscheid2021patientderivedipsccerebralorganoid pages 1-4, wegscheid2021patientderivedipsccerebralorganoid pages 16-17)

General NF1 models include conditional Nf1 knockout mice in Schwann-cell or neural-crest lineages, genetically engineered peripheral nerve-sheath tumor models, zebrafish, Drosophila, primary Schwann cells, tumor cell lines, xenografts, and patient-derived tumor models. They are valuable for RAS biology, neurofibroma initiation, cognition, and drug development, but deletion of Nf1 alone does not reproduce haploinsufficiency of the complete human interval. No validated mouse, zebrafish, or fly model carrying a syntenic deletion equivalent to the complete recurrent human 1.4-Mb interval was identified in the retrieved literature.

Recent research priorities and expert interpretation

The field is moving from a simple “more severe because more genes are deleted” model toward a multilayer model involving gene dosage, tissue mosaicism, second-hit tumor genetics, trans-acting modifiers, and deletion-induced chromatin reorganization. Pacot and colleagues’ 2024 study emphasizes deletion length, co-deleted genes, and background CNVs; Tritto and colleagues add position effects outside the deleted interval; the organoid work gives functional evidence for CRLF3-mediated neurogenesis. Together, these findings support interval-resolved diagnosis and personalized follow-up but do not yet justify gene-specific therapies. (pacot2024correlationbetweenlarge pages 1-2, tritto2024geneticepigeneticeffectsin pages 1-2, wegscheid2021patientderivedipsccerebralorganoid pages 8-9)

Highest-priority research gaps are prospective natural-history cohorts stratified by deletion type and mosaic fraction; standardized age-adjusted phenotype frequencies; microdeletion-specific MEK-inhibitor outcomes; longitudinal MPNST surveillance studies; single-cell/spatial analysis of neural and tumor tissues; and whole-interval animal or isogenic human models.

Key sources, publication dates, and links

1. Pacot L, et al. Correlation between large rearrangements and patient phenotypes in NF1 deletion syndrome: an update and review. BMC Medical Genomics. March 2024. DOI: 10.1186/s12920-024-01843-5. Human cohort, n=22, plus review. (pacot2024correlationbetweenlarge pages 1-2)
2. Tritto V, et al. Genetic/epigenetic effects in NF1 microdeletion syndrome: beyond the haploinsufficiency, looking at the contribution of not deleted genes. Human Genetics. June 2024;143:775–795. DOI: 10.1007/s00439-024-02683-0. Human qPCR, 4C-seq, and NGS study. (tritto2024geneticepigeneticeffectsin pages 1-2)
3. Perrino MR, et al. Update on Pediatric Cancer Surveillance Recommendations… Clinical Cancer Research. August 2024;30:4834–4843. DOI: 10.1158/1078-0432.CCR-24-1611. Expert surveillance consensus. (perrino2024updateonpediatric pages 6-8)
4. Büki G, et al. Genotype-Phenotype Associations in Patients With Type-1, Type-2, and Atypical NF1 Microdeletions. Frontiers in Genetics. June 2021;12:673025. DOI: 10.3389/fgene.2021.673025. Human cohort, n=17. (buki2021genotypephenotypeassociationsin pages 1-2, buki2021genotypephenotypeassociationsin pages 5-6)
5. Wegscheid ML, et al. Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis. Cell Reports. July 6, 2021;36:109315. DOI: 10.1016/j.celrep.2021.109315. Patient-derived organoid/in-vitro functional study. (wegscheid2021patientderivedipsccerebralorganoid pages 8-9, wegscheid2021patientderivedipsccerebralorganoid pages 1-4)
6. Kehrer-Sawatzki H, et al. Emerging genotype–phenotype relationships in patients with large NF1 deletions. Human Genetics. February 2017;136:349–376. DOI: 10.1007/s00439-017-1766-y. Landmark review and risk synthesis. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3, kehrersawatzki2017emerginggenotype–phenotyperelationships pages 17-18)

Evidence caveat: PMID values were not consistently exposed by the retrieved full-text metadata, so DOI URLs are supplied rather than inventing identifiers. Direct quotations above are limited to wording verifiably present in retrieved abstracts. Microdeletion-specific evidence remains dominated by small cohorts, reviews, and experimental models; general NF1 management recommendations are explicitly identified as extrapolations where applicable.

References

1. (pacot2024correlationbetweenlarge pages 1-2): Laurence Pacot, Milind Girish, Samantha Knight, Gill Spurlock, Vinod Varghese, Manuela Ye, Nick Thomas, Eric Pasmant, and Meena Upadhyaya. Correlation between large rearrangements and patient phenotypes in nf1 deletion syndrome: an update and review. BMC Medical Genomics, Mar 2024. URL: https://doi.org/10.1186/s12920-024-01843-5, doi:10.1186/s12920-024-01843-5. This article has 5 citations and is from a peer-reviewed journal.

2. (tritto2024geneticepigeneticeffectsin pages 1-2): Viviana Tritto, Paola Bettinaglio, Eleonora Mangano, Claudia Cesaretti, Federica Marasca, Chiara Castronovo, Roberta Bordoni, Cristina Battaglia, Veronica Saletti, Valeria Ranzani, Beatrice Bodega, Marica Eoli, Federica Natacci, and Paola Riva. Genetic/epigenetic effects in nf1 microdeletion syndrome: beyond the haploinsufficiency, looking at the contribution of not deleted genes. Human Genetics, 143:775-795, Jun 2024. URL: https://doi.org/10.1007/s00439-024-02683-0, doi:10.1007/s00439-024-02683-0. This article has 3 citations and is from a peer-reviewed journal.

3. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 1-3): Hildegard Kehrer-Sawatzki, Victor-Felix Mautner, and David N. Cooper. Emerging genotype–phenotype relationships in patients with large nf1 deletions. Human Genetics, 136:349-376, Feb 2017. URL: https://doi.org/10.1007/s00439-017-1766-y, doi:10.1007/s00439-017-1766-y. This article has 260 citations and is from a peer-reviewed journal.

4. (perrino2024updateonpediatric pages 6-8): Melissa R. Perrino, Anirban Das, Sarah R. Scollon, Sarah G. Mitchell, Mary-Louise C. Greer, Marielle E. Yohe, Jordan R. Hansford, Jennifer M. Kalish, Kris Ann P. Schultz, Suzanne P. MacFarland, Wendy K. Kohlmann, Philip J. Lupo, Kara N. Maxwell, Stefan M. Pfister, Rosanna Weksberg, Orli Michaeli, Marjolijn C.J. Jongmans, Gail E. Tomlinson, Jack Brzezinski, Uri Tabori, Gina M. Ney, Karen W. Gripp, Andrea M. Gross, Brigitte C. Widemann, Douglas R. Stewart, Emma R. Woodward, and Christian P. Kratz. Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, noonan syndrome, cbl syndrome, costello syndrome, and related rasopathies. Clinical Cancer Research, 30:4834-4843, Aug 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-1611, doi:10.1158/1078-0432.ccr-24-1611. This article has 52 citations and is from a highest quality peer-reviewed journal.

5. (OpenTargets Search: NF1 microdeletion syndrome): Open Targets Query (NF1 microdeletion syndrome, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (wegscheid2021patientderivedipsccerebralorganoid pages 8-9): Michelle L. Wegscheid, Corina Anastasaki, Kelly A. Hartigan, Olivia M. Cobb, Jason B. Papke, Jennifer N. Traber, Stephanie M. Morris, and David H. Gutmann. Patient-derived ipsc-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes crlf3 as a critical regulator of neurogenesis. Cell reports, 36:109315-109315, Jul 2021. URL: https://doi.org/10.1016/j.celrep.2021.109315, doi:10.1016/j.celrep.2021.109315. This article has 58 citations and is from a highest quality peer-reviewed journal.

7. (kehrersawatzki2017emerginggenotype–phenotyperelationships pages 17-18): Hildegard Kehrer-Sawatzki, Victor-Felix Mautner, and David N. Cooper. Emerging genotype–phenotype relationships in patients with large nf1 deletions. Human Genetics, 136:349-376, Feb 2017. URL: https://doi.org/10.1007/s00439-017-1766-y, doi:10.1007/s00439-017-1766-y. This article has 260 citations and is from a peer-reviewed journal.

8. (buki2021genotypephenotypeassociationsin pages 1-2): Gergely Büki, Anna Zsigmond, Márta Czakó, Renáta Szalai, Gréta Antal, Viktor Farkas, György Fekete, Dóra Nagy, Márta Széll, Marianna Tihanyi, Béla Melegh, Kinga Hadzsiev, and Judit Bene. Genotype-phenotype associations in patients with type-1, type-2, and atypical nf1 microdeletions. Frontiers in Genetics, Jun 2021. URL: https://doi.org/10.3389/fgene.2021.673025, doi:10.3389/fgene.2021.673025. This article has 26 citations and is from a peer-reviewed journal.

9. (buki2021genotypephenotypeassociationsin pages 14-15): Gergely Büki, Anna Zsigmond, Márta Czakó, Renáta Szalai, Gréta Antal, Viktor Farkas, György Fekete, Dóra Nagy, Márta Széll, Marianna Tihanyi, Béla Melegh, Kinga Hadzsiev, and Judit Bene. Genotype-phenotype associations in patients with type-1, type-2, and atypical nf1 microdeletions. Frontiers in Genetics, Jun 2021. URL: https://doi.org/10.3389/fgene.2021.673025, doi:10.3389/fgene.2021.673025. This article has 26 citations and is from a peer-reviewed journal.

10. (buki2021genotypephenotypeassociationsin pages 5-6): Gergely Büki, Anna Zsigmond, Márta Czakó, Renáta Szalai, Gréta Antal, Viktor Farkas, György Fekete, Dóra Nagy, Márta Széll, Marianna Tihanyi, Béla Melegh, Kinga Hadzsiev, and Judit Bene. Genotype-phenotype associations in patients with type-1, type-2, and atypical nf1 microdeletions. Frontiers in Genetics, Jun 2021. URL: https://doi.org/10.3389/fgene.2021.673025, doi:10.3389/fgene.2021.673025. This article has 26 citations and is from a peer-reviewed journal.

11. (wegscheid2021patientderivedipsccerebralorganoid pages 1-4): Michelle L. Wegscheid, Corina Anastasaki, Kelly A. Hartigan, Olivia M. Cobb, Jason B. Papke, Jennifer N. Traber, Stephanie M. Morris, and David H. Gutmann. Patient-derived ipsc-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes crlf3 as a critical regulator of neurogenesis. Cell reports, 36:109315-109315, Jul 2021. URL: https://doi.org/10.1016/j.celrep.2021.109315, doi:10.1016/j.celrep.2021.109315. This article has 58 citations and is from a highest quality peer-reviewed journal.

12. (wegscheid2021patientderivedipsccerebralorganoid pages 9-10): Michelle L. Wegscheid, Corina Anastasaki, Kelly A. Hartigan, Olivia M. Cobb, Jason B. Papke, Jennifer N. Traber, Stephanie M. Morris, and David H. Gutmann. Patient-derived ipsc-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes crlf3 as a critical regulator of neurogenesis. Cell reports, 36:109315-109315, Jul 2021. URL: https://doi.org/10.1016/j.celrep.2021.109315, doi:10.1016/j.celrep.2021.109315. This article has 58 citations and is from a highest quality peer-reviewed journal.

13. (wegscheid2021patientderivedipsccerebralorganoid pages 16-17): Michelle L. Wegscheid, Corina Anastasaki, Kelly A. Hartigan, Olivia M. Cobb, Jason B. Papke, Jennifer N. Traber, Stephanie M. Morris, and David H. Gutmann. Patient-derived ipsc-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes crlf3 as a critical regulator of neurogenesis. Cell reports, 36:109315-109315, Jul 2021. URL: https://doi.org/10.1016/j.celrep.2021.109315, doi:10.1016/j.celrep.2021.109315. This article has 58 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00